Abstract
Fine needle aspiration (FNA) has become increasingly popular in the evaluation of lymph nodes for lymphoproliferative disorders, but there are limitations to accurate subclassification of lymphoma using morphology alone. This case aims to expand diagnostic considerations of large B-cell populations identified on FNA material. We also address the significance of Epstein-Barr virus (EBV) DNA in the workup of patients with suspected lymphoma by FNA.
References
1.
Al-Abbadi
MA
, Barroca
H
, Bode-Lesniewska
B
, Calaminici
M
, Caraway
NP
, Chhieng
DF
, et al. A proposal for the performance, classification, and reporting of lymph node fine-needle aspiration cytopathology: the Sydney system
. Acta Cytol
. 2020
;64
(4
):306
–22
.2.
Frederiksen
JK
, Sharma
M
, Casulo
C
, Burack
WR
. Systematic review of the effectiveness of fine-needle aspiration and/or core needle biopsy for subclassifying lymphoma
.Arch Pathol Lab Med
. 2015
;139
(2
):245
–51
. 3.
Drylewicz
MR
, Watkin
MP
, Shetty
AS
, Lin
MF
, Salter
A
, Bartlett
NL
, et al. Formulating a treat plan in suspected lymphoma: ultrasound-guided core needle biopsy versus core needle biopsy and fine-needle aspiration of peripheral lymph nodes
. J Ultrasoun Med
. 2019
;38
:581
–6
.4.
Morton
LM
, Wang
SS
, Devesa
SS
, Hartge
P
, Weisenburger
DD
, Linet
MS
. Lymphoma incidence patterns by WHO subtype in the United States, 1992–2001
. Blood
. 2006
:107
(1
):265
–76
. 5.
Swerdlow
SH
, Campo
E
, Pileri
SA
, Harris
NL
, Stein
H
, Siebert
R
, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms
. Blood
. 2016
;127
(20
):2375
–90
. 6.
Nicol
TL
, Silberman
M
, Rosenthal
DL
, Borowitz
MJ
. The accuracy of combined cytopathologic and flow cytometric analysis of fine-needle aspirates of lymph nodes
. Am J Clin Pathol
. 2000
;114
(1
):18
–28
. 7.
Swart
GJ
, Wright
CA
. The utilization of fine needle aspiration biopsy (FNAB) and flow cytometry (FC) in the diagnosis and classification of non-Hodgkin B-cell and T-cell lymphomas
. Transfus Apher Sci
. 2010
;42
(2
):199
–207
. 8.
Morse
EE
, Yamase
HT
, Greenberg
BR
, Sporn
J
, Harshaw
SA
, Kiraly
TR
, et al. The Role of flow cytometry in the diagnosis of lymphoma: a critical analysis
. Ann Clin Lab Sci
. 1994
;24
(1
):6
–11
.9.
Bertram
HC
, Check
IJ
, Milano
MA
. Immunophenotyping large B-cell lymphomas. Flow cytometric pitfalls and pathologic correlation
. Am J Clin Pathol
. 2001
;116
(2
):191
–203
. 10.
Ohmoto
A
, Maeshima
AM
, Taniguchi
H
, Tanioka
K
, Makita
S
, Kitahara
H
, et al. Histopathological analysis of B-cell non-Hodgkin lymphomas without light chain restriction by using flow cytometry
. Leuk Lymphoma
. 2015
;56
(12
):3301
–5
. 11.
Federico
M
, Rudiger
T
, Bellei
M
, Nathwani
BN
, Luminari
S
, Coiffier
B
, et al. Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma: analysis of the international peripheral T-cell lymphoma project
. J clin Oncol
. 2013
;31
(2
):240
–6
. 12.
Vose
J
, Armitage
J
, Weisenburger
D
. International T-cell lymphoma project: international peripheral T-cell and natural killer T-cell lymphoma study: pathology findings and clinical outcomes
. J Clin Oncol
. 2008
;26
(25
):4124
–30
.13.
Lunning
MA
, Vose
JM
. Angioimmunoblastic T-cell lymphoma: the many-faced lymphoma
. Blood
. 2017
;129
(9
):1095
–102
. 14.
Attygalle
AD
, Chuang
SS
, Diss
TC
, Du
MQ
, Isaacson
PG
, Dogan
A
. Distinguishing angioimmunoblastic T-cell lymphoma from peripheral T-cell lymphoma, unspecified, using morphology, immunophenotype and molecular genetics
. Histopathology
. 2007
;50
(4
):498
–508
. 15.
Ellis
C
, Ramirez
J
, LaFond
AA
. Angioimmunoblastic T-cell lymphoma mimicking diffuse large B-cell lymphoma
. Cutis
. 2018
;102
(3
):179
–82
.16.
Szablewski
V
, Dereure
O
, René
C
, Tempier
A
, Durand
L
, Alame
M
, et al. Cutaneous localization of angioimmunoblastic T-cell lymphoma may masquerade as B-cell lymphoma or classical Hodgkin lymphoma: a histologic diagnostic pitfall
. J Cutan Pathol
. 2019
;46
(2
):102
–10
.17.
Beer
T
, Dorion
P
. Angioimmunoblastic T-cell lymphoma presenting with an acute serologic Epstein-Barr virus profile
. Hematol Rep
. 2015
;7
(2
):5893
. 18.
Delfau-Larue
MH
, de Leval
L
, Joly
B
, Plonquet
A
, Challine
D
, Parrens
M
, et al. Targeting intratumoral B cells with rituximab in addition to CHOP in angioimmunoblastic T-cell lymphoma. A clinicobiological study of the GELA
. Haematologica
. 2012
;97
(10
):1594
–602
. 19.
Liang
JH
, Lu
L
, Zhu
HY
, Li
W
, Fan
L
, Li
JY
, et al. The prognostic role of circulating Epstein-Barr Virus DNA copy number in angioimmunoblastic T-cell lymphoma treated with dose-adjusted EPOCH
. Cancer Res Treat
. 2019
;51
(1
):150
–7
. © 2020 S. Karger AG, Basel
2020
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.